By Counterforce Health Team in Alecensa (alectinib) —

How to Get Alecensa (alectinib) Covered by Blue Cross Blue Shield in Texas: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Alecensa Covered by Blue Cross Blue Shield in Texas

Blue Cross Blue Shield of Texas typically requires prior authorization for Alecensa (alectinib) with ALK-positive NSCLC confirmation and may require step therapy with crizotinib first. Start by gathering your ALK testing results and staging documentation. Submit your prior authorization through the BCBS Texas provider portal or have your oncologist call 1-877-719-2583. If denied, you have 180 days to appeal internally, then can request Independent Review Organization (IRO) external review through Texas Department of Insurance within 4 months of final denial.

Table of Contents

Coverage Requirements at a Glance

Requirement What It Means Where to Find It
Prior Authorization Required BCBS Texas requires approval before dispensing BCBS Texas Drug Lists
ALK-Positive Confirmation Molecular testing showing ALK rearrangement Pathology report with FISH or NGS results
Step Therapy May Apply May need to try crizotinib first Varies by specific BCBS Texas plan
Specialty Pharmacy Must use approved specialty pharmacy network MyPrime.com (pharmacy benefit manager)
Appeals Deadline 180 days from denial notice Texas Department of Insurance

Step-by-Step: Fastest Path to Approval

1. Confirm ALK-Positive Status

Who does it: Oncologist/pathology lab
Document needed: Molecular testing report showing ALK rearrangement via FISH or next-generation sequencing
Timeline: Results typically available within 7-14 days of biopsy

2. Gather Required Clinical Documentation

Who does it: Patient and care team
Documents needed:

  • Complete staging workup (CT chest/abdomen/pelvis, brain MRI, PET scan)
  • Pathology reports with histologic confirmation of NSCLC
  • ECOG performance status assessment
  • Baseline laboratory values (liver function, CBC, creatine kinase)

3. Submit Prior Authorization Request

Who does it: Prescribing oncologist
How to submit: BCBS Texas provider portal or call 1-877-719-2583
Expected timeline: 14 days for standard review, 72 hours for expedited
Required forms: PA request with clinical documentation and medical necessity letter

4. Address Step Therapy Requirements (If Applicable)

Who does it: Oncologist
Document needed: Medical exception request citing contraindications to crizotinib or clinical superiority rationale
Supporting evidence: NCCN guidelines, FDA labeling, patient-specific factors

5. Monitor Decision and Prepare for Appeals

Timeline: BCBS Texas typically responds within 14 days
If approved: Coordinate with specialty pharmacy for dispensing
If denied: Review denial letter and gather additional documentation for appeal

Common Denial Reasons & How to Fix Them

Denial Reason How to Overturn Required Documentation
Missing ALK test results Submit complete molecular pathology report FISH or NGS report showing ALK rearrangement
Step therapy not completed Request medical exception with contraindication letter Documentation of crizotinib allergy, interactions, or clinical superiority need
Insufficient staging information Provide complete diagnostic workup CT scans, brain MRI, PET results, staging summary
"Not medically necessary" Submit updated medical necessity letter FDA approval documentation, NCCN guidelines, patient-specific rationale
Non-formulary status File formulary exception request Comparative effectiveness data vs. formulary alternatives
Tip: For step therapy exceptions, emphasize CNS metastases if present—Alecensa has superior brain penetration compared to crizotinib, which is well-documented in clinical trials.

Medical Necessity Letter Template

Your oncologist should include these key elements in the medical necessity letter:

Patient Information Section:

  • Confirmed ALK-positive NSCLC diagnosis with staging
  • ALK testing methodology and results (include lab report)
  • Complete treatment history and prior therapy outcomes

Clinical Justification:

"[Patient Name] has ALK-positive non-small cell lung cancer confirmed by [testing method] on [date]. Based on FDA approval and NCCN Category 1 guidelines, Alecensa (alectinib) is indicated as [first-line/adjuvant] therapy for this condition.

[Include patient-specific factors such as:]
- CNS metastases requiring superior brain penetration
- Contraindications to alternative ALK inhibitors
- Prior treatment failures or intolerances
- Performance status and treatment goals"

Supporting Evidence:

  • FDA approval for ALK-positive NSCLC (metastatic and adjuvant settings)
  • NCCN guidelines recommending ALK inhibitors as preferred first-line therapy
  • Clinical trial data supporting efficacy (ALEX trial for metastatic, ALINA trial for adjuvant)

Appeals Process in Texas

Internal Appeals with BCBS Texas

Filing deadline: 180 days from denial notice
How to file:

  • Online: BCBS Texas member portal
  • Mail: BCBS Texas Complaints and Appeals, P.O. Box 660717, Dallas, TX 75266-0717
  • Phone: 1-888-657-6061 (TTY: 711)

Decision timeline: 30 days for pre-service appeals, 60 days for post-service, 72 hours for expedited

Independent Review Organization (IRO) External Review

Eligibility: Available for denials based on medical necessity, appropriateness, or experimental status
Filing deadline: Within 4 months of final internal denial
How to request: BCBS Texas provides IRO request form with final denial notice
Decision timeline: 20 days standard, 5 days for urgent cases
Cost: Paid by the insurance company
Outcome: Binding decision—if IRO approves, BCBS Texas must cover the treatment

Note: The IRO process in Texas is overseen by the Texas Department of Insurance. For assistance, call TDI at 1-800-252-3439 or the Office of Public Insurance Counsel at 1-877-611-6742.

Cost Support Options

Genentech Patient Foundation

  • Provides free medication for eligible uninsured patients
  • Income requirements: ≤400% of federal poverty level
  • Apply through Genentech-Access.com

Alecensa Co-pay Program

  • Reduces out-of-pocket costs for commercially insured patients
  • May cover up to $25,000 per year in co-pay assistance
  • Enroll at Alecensa.com

CancerCare Co-Payment Assistance Foundation

When to Get Help

Contact these Texas resources if you need assistance with your appeal:

Texas Department of Insurance

  • Phone: 1-800-252-3439
  • Website: TDI.Texas.gov
  • File complaints about insurance practices

Office of Public Insurance Counsel (OPIC)

  • Phone: 1-877-611-6742
  • Provides guidance on appealing denied claims
  • Free consumer advocacy services

Disability Rights Texas

  • Can assist with complex insurance appeals
  • Particularly helpful for Medicaid cases
  • Contact through DisabilityRightsTX.org
From our advocates: We've seen many Texas patients succeed with Alecensa appeals by focusing on the clinical superiority argument, especially when CNS metastases are present. The key is providing comprehensive documentation upfront—ALK testing, complete staging, and a detailed medical necessity letter citing specific NCCN recommendations. This composite experience shows that thorough preparation significantly improves approval odds.

Frequently Asked Questions

How long does BCBS Texas prior authorization take for Alecensa? Standard review takes up to 14 days. Expedited review (when delay could harm your health) takes 72 hours. Your oncologist can request expedited review by documenting medical urgency.

What if Alecensa isn't on my BCBS Texas formulary? You can request a formulary exception by having your oncologist submit a medical necessity letter explaining why formulary alternatives aren't appropriate for your specific case.

Do I need to try other ALK inhibitors first? This varies by specific BCBS Texas plan. Some require step therapy with crizotinib first, but exceptions are available for contraindications, prior failures, or clinical superiority needs like CNS metastases.

Can I get help with the appeals process? Yes. Contact the Texas Department of Insurance (1-800-252-3439) for guidance, or the Office of Public Insurance Counsel (1-877-611-6742) for free consumer advocacy assistance.

What happens if my internal appeal is denied? You can request Independent Review Organization (IRO) external review through the Texas Department of Insurance within 4 months. This review is conducted by independent medical experts and the decision is binding on your insurance company.

How much does Alecensa cost without insurance? The wholesale acquisition cost is approximately $19,466 per 240-count bottle (30-day supply). However, patient assistance programs can significantly reduce or eliminate out-of-pocket costs for eligible patients.

About Counterforce Health

Counterforce Health helps patients, clinicians, and specialty pharmacies turn insurance denials into successful appeals. Our platform analyzes denial letters and plan policies to create targeted, evidence-backed appeals that address the specific reasons for denial. We specialize in complex specialty drug cases like Alecensa, providing the clinical documentation and procedural expertise needed to navigate prior authorization and appeals processes effectively.

Throughout this process, remember that persistence often pays off. Many initial denials are overturned on appeal when proper documentation is provided. Counterforce Health has seen success rates improve significantly when appeals include comprehensive clinical evidence, proper procedural compliance, and targeted responses to the insurer's specific denial reasons.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage policies vary by plan and change frequently. Always verify current requirements with your specific BCBS Texas plan and consult with your healthcare provider for medical decisions. For personalized assistance with insurance appeals, consider consulting with patient advocacy organizations or legal professionals specializing in healthcare coverage.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.